Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 734-744

  Van Hal, S J ^a,b   Paterson, D L ^c   Lodise, T P ^d  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

CLINICAL PRACTICE; COCHRANE LIBRARY; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; EMBASE; HUMAN; MEDLINE; META ANALYSIS; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; HUMANS; KIDNEY; RENAL DIALYSIS; VANCOMYCIN;

EID: 84872848638     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01568-12     Document Type: Review

References (63)

1. Levine DP. 2006. Vancomycin: A history. Clin. Infect. Dis. 42(Suppl 1): S5-S12.
2. Popovich KJ, Weinstein RA, Hota B. 2008. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin. Infect. Dis. 46:787-794.
3. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O'Boyle C, Danila RN, Lynfield R. 2003. Comparison of community-and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290:2976-2984.
4. Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, Harriman K, Harrison LH, Lynfield R, Farley MM. 2005. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352:1436-1444.
5. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Talan M JRDA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-e55.
6. van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis. Clin. Infect. Dis. 54:755-771.
7. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43:925-942.
8. Kullar R, Davis SL, Levine DP, Rybak MJ. 2011. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: Support for consensus guidelines suggested targets. Clin. Infect. Dis. 52:975-981.
9. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, JR, Craig W, Billeter M, Dalovisio JR, Levine DP. 2009. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98.
10. Kullar R, Davis SL, Taylor TN, Kaye KS, Rybak MJ. 2012. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy 32:195-201.
11. Moellering RC, Jr. 2006. Vancomycin: A 50-year reassessment. Clin. Infect. Dis. 42(Suppl 1):S3-S4.
12. Rybak MJ. 2006. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42(Suppl 1):S35-S39.
13. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch. Intern. Med. 166:2138-2144.
14. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. 2008. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J. Antimicrob. Chemother. 62:168-171.
15. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. 2007. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin. Ther. 29:1107-1115.
16. Lodise TP, Lomaestro B, Graves J, Drusano GL. 2008. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52:1330-1336.
17. Gupta A, Biyani M, Khaira A. 2011. Vancomycin nephrotoxicity: Myths and facts. Neth. J. Med. 69:379-383.
18. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. 2010. Vancomycinassociated nephrotoxicity: Grave concern or death by character assassination? Am. J. Med. 123:182e1-182e7.
19. Wong-Beringer A, Joo J, Tse E, Beringer P. 2011. Vancomycinassociated nephrotoxicity: A critical appraisal of risk with high-dose therapy. Int. J. Antimicrob. Agents 37:95-101.
20. Aston JL, Dortch MJ, Dossett LA, Creech CB, May AK. 2010. Risk factors for treatment failure in patients receiving vancomycin for hospitalacquired methicillin-resistant Staphylococcus aureus pneumonia. Surg. Infect. (Larchmt.) 11:21-28.
21. Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD. 2011. Relationship between vancomycin trough concentrations and nephrotoxicity: A prospective multicenter trial. Antimicrob. Agents Chemother. 55:5475-5479.
22. Cano EL, Haque NZ, Welch VL, Cely CM, Peyrani P, Scerpella EG, Ford KD, Zervos MJ, Ramirez JA, Kett DH. 2012. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: Retrospective analysis of the IMPACT-HAP database. Clin. Ther. 34:149-157.
23. Chung J, Oh JM, Cho EM, Jang HJ, Hong SB, Lim CM, Koh YS. 2011. Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients. Anaesth. Intensive Care 39:1030-1037.
24. Cohen E, Dadashev A, Drucker M, Samra Z, Rubinstein E, Garty M. 2002. Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J. Antimicrob. Chemother. 49:155-160.
25. Colares VS, Oliveira RB, Abdulkader RC. 2006. Nephrotoxicity of vancomycin in patients with normal serum creatinine. Nephrol. Dial. Transplant. 21:3608. doi:10.1093/ndt/gfl426.
26. Elting LS, Rubenstein EB, Kurtin D, Rolston KV, Fangtang J, Martin CG, Raad II, Whimbey EE, Manzullo E, Bodey GP. 1998. Mississippi mud in the 1990s: Risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 83:2597-2607.
27. Fisher BT, Zaoutis TE, Leckerman KH, Localio R, Aplenc R. 2010. Risk factors for renal failure in pediatric patients with acute myeloid leukemia: A retrospective cohort study. Pediatr. Blood Cancer 55:655-661.
28. Frymoyer A, Guglielmo BJ, Wilson SD, Scarpace SB, Benet LZ, Hersh AL. 2011. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy 31:871-876.
29. Hahn-Ast C, Glasmacher A, Arns A, Muhling A, Orlopp K, Marklein G, Von Lilienfeld-Toal M. 2008. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: Is the different toxicity profile clinically relevant? Infection 36:54-58.
30. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. 2010. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin. Drug Saf. 9:9-14.
31. Kralovicova K, Spanik S, Halko J, Netriova J, Studena-Mrazova M, Novotny J, Grausova S, Koren P, Krupova I, Demitrovicova A, Kukuckova E, Krcmery V, Jr. 1997. Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients? J. Chemother. 9:420-426.
32. Kullar R, Leonard SN, Davis SL, Delgado G, Jr, Pogue JM, Wahby KA, Falcione B, Rybak MJ. 2011. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy 31:441-448.
33. Lahoti A, Kantarjian H, Salahudeen AK, Ravandi F, Cortes JE, Faderl S, O'Brien S, Wierda W, Mattiuzzi GN. 2010. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or highrisk myelodysplastic syndrome. Cancer 116:4063-4068.
34. Lemaire X, Loiez C, Valette M, Migaud H, Dubreuil L, Yazdanpanah Y, Senneville E. 2011. Comparison of vancomycin and teicoplanin trough serum levels in patients with infected orthopedic devices: New data for old therapies. J. Infect. Chemother. 17:370-374.
35. Li J, Udy AA, Kirkpatrick CM, Lipman J, Roberts JA. 2012. Improving vancomycin prescription in critical illness through a drug use evaluation process: A weight-based dosing intervention study. Int. J. Antimicrob. Agents 39:69-72.
36. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. 2009. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 49:507-514.
37. Marinho DS, Huf G, Ferreira BL, Castro H, Rodrigues CR, Sousa VP, Cabral LM. 2011. The study of vancomycin use and its adverse reactions associated to patients of a brazilian university hospital. BMC Res. Notes 4:236. doi:10.1186/1756-0500-4-236.
38. McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J. 2011. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J. Pediatr. 158:422-426.
39. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A. 2011. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob. Agents Chemother. 55:3278-3283.
40. Moffett BS, Kim S, Edwards M. 2011. Vancomycin nephrotoxicity may be overstated. J. Pediatr. 158:865-866. (Letter.)
41. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. 2012. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: A case-control study. Clin. Infect. Dis. 54:51-58.
42. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. 2011. Vancomycin: We can't get there from here. Clin. Infect. Dis. 52:969-974.
43. Prabaker KK, Tran TP, Pratummas T, Goetz MB, Graber CJ. 2012. Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans. J. Hosp. Med. 7:91-97.
44. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. 2010. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am. J. Med. 123:1143-1149.
45. Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. 2011. Vancomycin dosing in critically ill patients: Robust methods for improved continuous-infusion regimens. Antimicrob. Agents Chemother. 55: 2704-2709.
46. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME. 2011. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin. Infect. Dis. 52:31-40.
47. Shen WC, Chiang YC, Chen HY, Chen TH, Yu FL, Tang CH, Sue YM. 2011. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Nephrology (Carlton) 16:697-703.
48. Spapen HD, Janssen van Doorn K, Diltoer M, Verbrugghe W, Jacobs R, Dobbeleir N, Honore PM, Jorens PG. 2011. Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. Ann. Intensive Care 1:26.
49. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC. 2011. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 66:2386-2392.
50. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. 2012. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study. Clin. Infect. Dis. 54:621-629.
51. Zimmermann AE, Katona BG, Plaisance KI. 1995. Association of vancomycin serum concentrations with outcomes in patients with grampositive bacteremia. Pharmacotherapy 15:85-91.
52. Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Muller M, Tschernko E. 2009. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: Continuous versus intermittent infusion. Anesthesiology 111:356-365.
53. Corrado ML. 2010. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl 4):iv67-iv71.
54. Cruz DN, Ricci Z, Ronco C. 2009. Clinical review: RIFLE and AKIN-time for reappraisal. Crit. Care 13:211. doi:10.1186/cc7759.
55. King DW, Smith MA. 2004. Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicol. In Vitro 18:797-803.
56. Celik I, Cihangiroglu M, Ilhan N, Akpolat N, Akbulut HH. 2005. Protective effects of different antioxidants and amrinone on vancomycininduced nephrotoxicity. Basic Clin. Pharmacol. Toxicol. 97:325-332.
57. Oktem F, Arslan MK, Ozguner F, Candir O, Yilmaz HR, Ciris M, Uz E. 2005. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: Protection by erdosteine. Toxicology 215:227-233.
58. Cetin H, Olgar S, Oktem F, Ciris M, Uz E, Aslan C, Ozguner F. 2007. Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model. Clin. Exp. Pharmacol. Physiol. 34:1181-1185.
59. Hodoshima N, Nakano Y, Izumi M, Mitomi N, Nakamura Y, Aoki M, Gyobu A, Shibasaki S, Kurosawa T. 2004. Protective effect of inactive ingredients against nephrotoxicity of vancomycin hydrochloride in rats. Drug Metab. Pharmacokinet. 19:68-75.
60. Toyoguchi T, Takahashi S, Hosoya J, Nakagawa Y, Watanabe H. 1997. Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits. Antimicrob. Agents Chemother. 41:1985-1990.
61. Le Moyec L, Racine S, Le Toumelin P, Adnet F, Larue V, Cohen Y, Leroux Y, Cupa M, Hantz E. 2002. Aminoglycoside and glycopeptide renal toxicity in intensive care patients studied by proton magnetic resonance spectroscopy of urine. Crit. Care Med. 30:1242-1245.
62. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. 2004. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 8:R204-R212.
63. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. 2007. Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit. Care 11:R31. doi:10.1186 /cc5713.